No Data
No Data
Possible Bearish Signals With Edgewise Therapeutics Insiders Disposing Stock
RBC: The first half of the year is expected to welcome positive catalysts. COMPASS Pathways (CMPS.US) and 12 other mid-small pharmaceutical stocks are worth a look.
RBC believes that some important catalysts for small and mid-cap Biotechnology companies in the first quarter of 2025 may have a significant impact on the Stocks it covers.
Should You Invest in Edgewise Therapeutics (EWTX)?
J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $45
Express News | Edgewise Therapeutics Inc : JP Morgan Raises Target Price to $45 From $44
Edgewise Therapeutics Insider Sold Shares Worth $276,776, According to a Recent SEC Filing